2024-11-22 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison and Divergence:**

Johnson & Johnson (JNJ), a multinational healthcare company developing and manufacturing medical devices, pharmaceuticals, and consumer packaged goods, has significantly underperformed the S&P 500 (VOO) over the analyzed period.  While JNJ shows a cumulative return of 36.34%, VOO boasts a 126.85% return. This results in a substantial negative divergence of -90.51%, placing it at the 3.39 percentile of its historical range of divergence from the S&P 500.  The provided alpha and beta analysis shows that while JNJ generally outperforms the market in terms of CAGR (Compound Annual Growth Rate) in most periods, it demonstrates lower betas in recent periods suggesting a lower sensitivity to overall market movements.  The considerable underperformance in recent years is notable.


**2. Recent Price Movement:**

* **Closing Price:** $155.5
* **5-day Moving Average:** $154.08
* **20-day Moving Average:** $156.65
* **60-day Moving Average:** $161.30

The price is currently below its 20-day and 60-day moving averages, suggesting a short-term downtrend. The 5-day moving average being below the current price suggests slight upward momentum very recently.


**3. Technical Indicators and Expected Return:**

* **RSI (Relative Strength Index):** 36.26 – This indicates the stock is currently in oversold territory, suggesting potential for a price bounce.
* **PPO (Price Oscillator):** -0.05 – A negative value suggests bearish momentum.
* **20-Day Relative Divergence:** -5.05 – Indicates a recent short-term decline in relative performance against the S&P 500.
* **Expected Return:** 0.0% – The model predicts no significant excess return over the S&P 500 for long-term (2+ years) investment at this time.  This is consistent with the historical underperformance relative to the S&P 500.  The provided data does not account for potential future market changes or company-specific developments that could impact this expectation significantly.

**4. Recent Financial Performance:**

The provided EPS and Revenue data shows some volatility. While revenue remains relatively stable, EPS shows significant fluctuation. The October 2024 EPS of $1.12 is considerably lower than previous quarters.  Further analysis is needed to determine the reason for this drop.  A comparison to analyst expectations for the October 2024 earnings is crucial for a complete evaluation of this recent performance.

**5. Financial Statements Analysis:**

* **Revenue and Profitability:**  High and consistent revenue figures. Profit margins are impressively stable and high, exceeding 68% in most quarters.
* **Capital and Profitability:**  Equity is relatively stable with minor fluctuations. Return on Equity (ROE) shows some volatility but is generally positive, although the exceptionally high ROE in Q3 2023 needs further investigation to identify the underlying cause.  


**6. News and Recent Issues:**

*(This section requires access to real-time news sources like Shacknews, FINBOLD, and financial news websites.  I need to pull current information to fulfill this section.  Please provide the date of the analysis to make this information more accurate.)*  Analysis of recent news articles (within the past two days) concerning earnings announcements, market outlook, analyst opinions and performance highlights will be added here once current data is available.


**7.  Overall Analysis:**

JNJ shows a history of solid financial performance, indicated by high revenue and profit margins.  However, it has significantly underperformed the S&P 500 in recent years, despite periods of strong growth prior. Current technical indicators suggest potential for a short-term price bounce due to the oversold conditions but bearish momentum persists.  The recent EPS drop warrants further scrutiny and comparison with analyst predictions to assess the impact on future performance.   Long-term investment prospects depend heavily on the resolution of the factors contributing to the recent underperformance relative to the broader market.  Further detailed fundamental analysis, including a deeper dive into the October 2024 EPS results and investigation of the unusually high Q3 2023 ROE, are required before making definitive investment recommendations.


**8. Disclaimer:** This analysis is for informational purposes only and does not constitute financial advice.  Investing involves risk, and past performance is not indicative of future results.  Conduct thorough research and consult a financial advisor before making any investment decisions.
